Third-party contract medical representatives have been available to pharmaceutical marketing executives in the USA and Europe for a long time. Providers of these services are growing rapidly as in-house staff levels are pegged to minimum rather than maximum personnel demands.
Part-time rep services are not available in Japan, but this is about to change with the launch of a new company, Nippon Pharma Promotion. However, the model differs from its western counterparts because of the unique structure of pharmaceutical promotion and distribution in Japan.
There are 210,000 practicing physicians in Japan who prescribe and typically dispense drugs, all of which are covered by some form of insurance. 62%, or 130,000 doctors, work in medical institutions with 100 beds or more. This market represents 52% of drug sales and is concentrated in the larger urban centers. The "alternate" market comprises 80,000 doctors practicing in hospitals with 99 beds or less, or in clinics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze